Your browser doesn't support javascript.
loading
Pulmonary veno-occlusive disease: illustrative cases and literature review.
Lechartier, Benoit; Boucly, Athénaïs; Solinas, Sabina; Gopalan, Deepa; Dorfmüller, Peter; Radonic, Teodora; Sitbon, Olivier; Montani, David.
Afiliación
  • Lechartier B; Assistance Publique - Hôpitaux de Paris (AP-HP), Department of Respiratory and Intensive Care Medicine, Pulmonary Hypertension National Referral Center, DMU 5 Thorinno, Hôpital Bicêtre, Le Kremlin-Bicêtre, France.
  • Boucly A; Université Paris-Saclay, School of Medicine, Le Kremlin-Bicêtre, France.
  • Solinas S; INSERM UMR_S 999 "Pulmonary Hypertension: Pathophysiology and Novel Therapies", Hôpital Marie Lannelongue, Le Plessis-Robinson, France.
  • Gopalan D; Respiratory Division, Lausanne University Hospital (CHUV), Lausanne, Switzerland.
  • Dorfmüller P; Assistance Publique - Hôpitaux de Paris (AP-HP), Department of Respiratory and Intensive Care Medicine, Pulmonary Hypertension National Referral Center, DMU 5 Thorinno, Hôpital Bicêtre, Le Kremlin-Bicêtre, France.
  • Radonic T; Université Paris-Saclay, School of Medicine, Le Kremlin-Bicêtre, France.
  • Sitbon O; INSERM UMR_S 999 "Pulmonary Hypertension: Pathophysiology and Novel Therapies", Hôpital Marie Lannelongue, Le Plessis-Robinson, France.
  • Montani D; Assistance Publique - Hôpitaux de Paris (AP-HP), Department of Respiratory and Intensive Care Medicine, Pulmonary Hypertension National Referral Center, DMU 5 Thorinno, Hôpital Bicêtre, Le Kremlin-Bicêtre, France.
Eur Respir Rev ; 33(171)2024 Jan 31.
Article en En | MEDLINE | ID: mdl-38232988
ABSTRACT
Pulmonary veno-occlusive disease (PVOD), also known as "pulmonary arterial hypertension (PAH) with overt features of venous/capillary involvement", is a rare cause of PAH characterised by substantial small pulmonary vein and capillary involvement, leading to increased pulmonary vascular resistance and right ventricular failure. Environmental risk factors have been associated with the development of PVOD, such as occupational exposure to organic solvents and chemotherapy, notably mitomycin. PVOD may also be associated with a mutation in the EIF2AK4 gene in heritable forms of disease. Distinguishing PVOD from PAH is critical for guiding appropriate management. Chest computed tomography typically displays interlobular septal thickening, ground-glass opacities and mediastinal lymphadenopathy. Life-threatening pulmonary oedema is a complication of pulmonary vasodilator therapy that can occur with any class of PAH drugs in PVOD. Early referral to a lung transplant centre is essential due to the poor response to therapy when compared with other forms of PAH. Histopathological analysis of lung explants reveals microvascular remodelling with typical fibrous veno-occlusive lesions. This review covers the main features distinguishing PVOD from PAH and two clinical cases that illustrate the challenges of PVOD management.
Asunto(s)

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Enfermedad Veno-Oclusiva Pulmonar / Trasplante de Pulmón / Hipertensión Arterial Pulmonar Tipo de estudio: Etiology_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: Eur Respir Rev Año: 2024 Tipo del documento: Article País de afiliación: Francia

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Enfermedad Veno-Oclusiva Pulmonar / Trasplante de Pulmón / Hipertensión Arterial Pulmonar Tipo de estudio: Etiology_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: Eur Respir Rev Año: 2024 Tipo del documento: Article País de afiliación: Francia